Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On Pfizer Is Somewhat Muted; Says $1.5B Of Cost Savings Is Only From Phase One Of A Multiple Phase Program